Premium
Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients
Author(s) -
Martial Lisa C.,
Jacobs Bart A. W.,
Cornelissen Elisabeth A. M.,
Haan Anton F. J.,
Koch Birgit C. P.,
Burger David M.,
Aarnoutse Rob E.,
Schreuder Michiel F.,
Brüggemann Roger J.M.
Publication year - 2016
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12695
Subject(s) - medicine , transplantation , pharmacokinetics , area under the curve , therapeutic drug monitoring , creatinine , urology , mycophenolic acid , single center , renal transplant , gastroenterology , mycophenolate , kidney transplantation , surgery
MPA is an immunosuppressive agent used to prevent graft rejection after renal transplantation. MPA shows considerable inter‐ and intraindividual variability in exposure in children and has a defined therapeutic window, and TDM is applied to individualize therapy. We aimed to study the exposure to MPA measured as the AUC in pediatric renal transplant patients, to identify factors influencing exposure and to assess target attainment. Children transplanted between 1998 and 2014 in a single center were included. Two groups were identified: Group 1 ( AUC <3 wk post‐transplantation) and Group 2 ( AUC >18 months post‐transplantation). Therapeutic targets were set at: AUC 0–12h of 30–60 mg h/L. A total of 39 children were included in Group 1 (median age 13.3 yr) vs. 14 in Group 2 (median age 13.4 yr). AUC 0–12h was 29.7 mg h/L in Group 1 and 56.6 mg h/L in Group 2, despite a lower dosage in Group 2 (584 and 426 mg/m 2 , respectively). About 46% of patients reached the target AUC 0–12h in Group 1. Time since transplantation and serum creatinine were significantly associated with MPA exposure (p < 0.001), explaining 36% of the variability. Individualization of the mycophenolate dose by more intense and more early TDM could improve target attainment.